IMPACT Medicom

The Canadian Hematology Consensus Group, or CHCG, is a national collaboration of Canadian hematologists and healthcare professionals dedicated to improving patient care through the development of National consensus recommendations in hematologic malignancies.

Our most recent consensus paper has  been published in Current Oncology. The paper provides treatment recommendations for hematologists managing patients with relapsed and/or refractory FL. In this episode, we will discuss the content of the paper with Dr Lemieux, who is a lead author and a member of the CHCG scientific committee. 

Our Guest

Dr Lemieux is a Hematologist at the CHU de Québec-Université Laval in Quebec city, Quebec and a Canadian expert in the treatment of follicular lymphoma.

This podcast episode has been funded by Merck Canada. 

Dr. Carolyn Owen, Chair of the Canadian Hematology Consensus Group (CHCG), introduces the CHCG and discusses its mission to develop evidence-based Canadian consensus recommendations in areas of unmet need in hematology. In this video, Dr. Owen highlights the group’s multidisciplinary expert panel, rigorous methodology, and current initiatives, including consensus papers on relapsed/refractory follicular lymphoma and first-line diffuse large B-cell lymphoma.

The CHCG was founded by Anna Christofides, President of IMPACT Medicom Inc. and Founder & Managing Director of the CHCG, to provide the scientific and operational infrastructure required to develop high-quality Canadian consensus recommendations and support knowledge translation in hematology.

Learn more about the CHCG:
www.canadianconsensusgroup.com

In this episode with Dr Robert Puckrin, we discuss the unmet needs of double-exposed patients with CLL/SLL, as well as the current and novel treatments that can address this gap. 

Our guest

Dr. Puckrin is a Hematologist and Clinician Investigator at the Arthur Child Comprehensive Cancer Centre and Alberta Blood and Marrow Transplant Program. He is also a clinical assistant professor at the University of Calgary. Dr Puckrin has received honoraria for advisory boards and/or speaking engagements from Abbvie, Astrazeneca, BeOne, Eli Lilly, Incyte, Kite, Janssen,Pfizer, Roche, and Seagen.

Please provide your feedback on this episode by filling out this quick survey at the following link: https://survey.decipherinc.com/survey/selfserve/53b/g00e/2511135

Funding for this episode was provided by Eli Lilly Canada.

This information is intended solely for educational purposes and is not intended to promote the use of any Eli Lilly Canada medication. All materials or information provided by Eli Lilly Canada Inc. for this learning program comply with applicable regulatory standards.​

Editorial control of this learning program resides with the speaker within the parameters of the Innovative Medicines Canada Code and Eli Lilly Policy.

Eli Lilly Canada supports discussion of its products consistent with the approved prescribing information in the product monograph.

Any off-label discussion of products represents the personal opinion of the speaker.​

In this podcast episode, Dr. Dimitrios Coutsinos describes a video capsule series involving three educational videos of lung resections using minimally invasive video-assisted thoracic surgery (VATS) following neoadjuvant immunotherapy in patients with lung cancer. 

Our Host:

Dr. Dimitrios Coutsinos is a thoracic surgeon at Interior Health Authority and a professor at the University of British Columbia. Dr. Coutsinos has received honoraria for advisory board attendance from: AstraZeneca, Bristol Myers Squibb, Intuitive Surgica, Johnson and Johnson, Merck, and Roche.

Video Capsule Series:

To access the video capsule series, please visit: https://www.impactmedicom.com/video-capsules.

This podcast episode and video capsule series was funded by Merck Canada.

If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com.

In this podcast episode, we discuss clinical trial updates in chronic lymphocytic leukemia from the 2025 European Hematology Association annual congress in Milan, Italy and the 18th International Conference on Malignant Lymphoma in Lugano, Switzerland. The discussion involves an analysis of the data from abstracts investigating combination and novel therapies for the treatment of CLL.

Our Host:
Dr. Constantine Tam is Head of Lymphoma Service at Alfred Health and Professor of Haematology at Monash University in Melbourne, Australia. Prior to joining Alfred, Dr. Tam completed a Leukemia Fellowship at MD Anderson Cancer Centre in Houston, Texas and served as Disease Group Lead for Low Grade Lymphoma and CLL at Peter MacCallum Cancer Centre & Royal Melbourne Hospital for over 10 years. He is the global lead for the BTK inhibitor zanubrutinib, overseeing its development from the first human dosed to international licensing studies. He also played key roles in the first global study of ibrutinib and venetoclax in CLL and the pivotal study of Tisagenlecleucel in diffuse large B-cell lymphoma.

Our guests:

Dr. John Gribben is Consultant Hematologist and Medical Oncologist at the Barts Cancer Institute, Barts NHS Trust and Professor in Medical Oncology at The London School of Medicine, Queen Mary University of London, in London, UK. Dr. Gribben trained in Haematology at University College London and in Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School, where he remained on the faculty for 17 years before returning to the UK. Dr. Gribben serves on many international committees, including as Chair of the international workshop for NHL, co-Chair of the international workshop for CART, and founding member of the CLL Research Consortium. He also serves as an executive board member of the European Hematology Association, where he previously served as President from 2019-2021.

Dr. Stephan Stilgenbauer is professor of medicine and Medical Director of the Comprehensive Cancer Center Ulm (CCCU), Head Early Clinical Trials Unit (ECTU), and Head Division of CLL Dept. of Internal Medicine III at Ulm University, Germany. He received his medical training at Heidelberg Medical School, Germany, and was trained in internal medicine and hematology-oncology at the Universities of Heidelberg and Ulm. He spent a postdoctoral fellowship at the German Cancer Research Center (DKFZ) in Heidelberg. His research focus is on the molecular pathogenesis and evolution as well as development of novel treatment strategies in hematological malignancies.

If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/)

In this podcast episode, Dr. Diego Delgado discusses how to manage patients with mixed phenotype hereditary transthyretin amyloidosis over the course of their disease from initial symptoms and clinical suspicion, to monitoring patients on treatment. For additional details, please see the related video publication by Dr. Delgado and colleagues: https://www.sciencedirect.com/science/article/pii/S2589790X25001180

Our Guest: 

Dr. Diego Delgado is the Director of the Cardiac Amyloid Centre and Associate Professor in the Division of Cardiology and Cardiac Transplantation at the University Health Network in Toronto, Ontario. Dr. Diego Delgado graduated in Medicine from the Universidad del Salvador in Buenos Aires, Argentina. He completed his Internal Medicine and Cardiology training in Hospital Espanol in Buenos Aires. Subsequently he completed a research fellowship in cardiac transplantation at Rush Presbyterian St Luke’s Medical Center in Chicago, US and a research/clinical fellowship in heart failure and transplantation at the Toronto General Hospital.

Dr. Delgado completed his Maters of Science in Clinical Epidemiology at the University of Toronto and the Leadership Development Program at Rotman School of Management in Toronto. He is the author of more than 100 publications in the area of heart failure, transplantation and mechanical assist devices. His interests are immunologic aspects of heart failure and transplantation and cardio oncology.

This podcast episode was sponsored by AstraZeneca Canada. 

For other medical education content, please subscribe to our podcast or visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

Dans cet épisode du balado, Dre Geneviève Matte discutera de la prise en charge des patients atteints d'amyloïdose à transthyrétine héréditaire à phénotype mixte tout au cours de leur maladie, des premiers symptômes jusqu’au suivi des patients sous traitement. Pour plus de détails, veuillez consulter la publication connexe du Dre Matte et de ses collègues : https://www.sciencedirect.com/science/article/pii/S2589790X25001180 

À propos de notre invité : 

Dre Geneviève Matte est neurologue-chercheure au Centre Hospitalier de l’Université de Montréal-Centre de Recherche du CHUM et professeure adjoint de clinique au Département de neurosciences de l’Université de Montréal depuis 2010.  Elle a obtenu son diplôme de médecine de l’Université McGill en 2003, puis a réussi sa résidence en neurologie adulte à l’Université de Montréal en 2008. Dre Matte a ensuite acquis une expertise en médecine neuromusculaire à la Cleveland Clinic Foundation à Cleveland, Ohio. Depuis 2013, elle est directrice de la Clinique SLA et des maladies du neurone moteur du CHUM.  Elle est aussi leader pour la neurologie dans le programme de référence en amyloïdose du CHUM, recevant des consultations de toute la province.  De 2020 à 2024, Dre Matte a été co-présidente du Réseau Canadien de Recherche en SLA (CALS).  Elle est désormais membre du comité exécutif de la Société Canadienne d’Amyloïdose.

Cet épisode du balado a été commanditée par AstraZeneca Canada. 

Pour d'autres contenus éducatifs médicaux, veuillez vous abonner à notre balado ou visitez notre site web à l'adresse suivante : https://www.impactmedicom.com (https://www.impactmedicom.com/). 

(FRENCH) In this podcast episode, which follows this introduction in French, Dr Christopher Lemieux summarizes a paper by Dr Abramson, et al. on the management of Peripheral Neuropathy Associated with Brentuximab Vedotin in the Frontline Treatment of classical Hodgkin Lymphoma.

Our Guest
Dr Lemieux is a Hematologist at the Centre hospitalier universitair de Québec-Université Laval. He is also a member of the immunocellular therapy network fellowship program at Université Laval.

This podcast episode was sponsored by Pfizer Canada Inc.

If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Michael Chu discusses the management of peripheral neuropathy associated with the use of brentuximab vedotin for the first-line treatment of classical Hodgkin Lymphoma.

Our Guest
Dr. Michael Chu is a clinician scientist at the Cross Cancer Institute and an Associate Professor at the University of Alberta in Edmonton, Alberta.

This podcast episode was sponsored by Pfizer Canada Inc.

If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).

In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the treatment of CLL presented at the American Society of Hematology (or ASH) meeting in San Diego, CA. The discussion involves an analysis of the data from 8 presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada. 

Our Guests:
Dr. Versha Banerji is a hematologist at Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba.

Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts.

This podcast episode was sponsored by BeiGene Canada ULC.

If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com (https://www.impactmedicom.com/).